Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization Post published:June 27, 2022 Post category:Press Release
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome Post published:May 22, 2022 Post category:Press Release
Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties Post published:May 2, 2022 Post category:Press Release
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial Post published:March 14, 2022 Post category:Press Release
Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases Post published:November 30, 2021 Post category:Press Release
Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG” Post published:November 3, 2021 Post category:Press Release
Bright Minds Biosciences Provides Scientific Update Post published:September 22, 2021 Post category:Press Release
Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity Post published:August 18, 2021 Post category:Press Release
Bright Minds Biosciences Announces Application to List on Nasdaq Post published:June 16, 2021 Post category:Press Release
Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021 Post published:May 17, 2021 Post category:Press Release